BioTech

Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

VIVUS Inc. (NASDAQ:VVUS) stock was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $15.00. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 1.00% in last session and finished the day at $6.09. Traded volume was 5,364,675 million shares in the last session and the average volume of the stock remained 2.45 million shares. The beta of the stock remained 1.28. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.20%

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Feb. 27 provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. The company said its fourth quarter revenues totaled $6.5 million, including $2.4 million in BELVIQ product revenue, of which $2.3 million represented 31.5% of Eisai’s net product sales and $0.1 million related to redemptions of the 15-day free trial voucher. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose percent to $4.45 yesterday on volume of 6.25 million shares. The intra-day range of the stock was $6.38 to $6.85. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a market capitalization of $1.49 million.

Ariad Pharmaceuticals (NASDAQ:ARIA)‘s stock had its “neutral” rating restated by stock analysts at Goldman Sachs in a report issued on Thursday, Analyst Ratings Network.com reports. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on Mar 3, 2014 reported a decrease of -1.27% to the closing price of $8.58. Its fifty two weeks range is $2.15 -$23.00. The total market capitalization recorded $1.59 billion. The overall volume in the last trading session was 13,038,400 million shares. In its share capital, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has 185.70 million outstanding shares.

Analysts at Zacks reiterated a “neutral” rating on shares of MannKind Corporation (NASDAQ:MNKD) in a research note on Thursday. On Monday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -0.97% to close the day at $6.13. Its monthly performance is recorded as 13.52%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 22.85%.